If your mind races at night, sleep keeps slipping away, or your head feels foggy and flat, you may have come across kratom as a possible help. Here’s the plain answer: kratom is not FDA approved for any use, and the FDA says it isn’t lawfully marketed in the U.S. as a drug product, a dietary supplement or a food additive. The human studies so far mostly enrolled healthy volunteers, and NCCIH says kratom has not been shown to be safe and effective for this or any other medical use.
Why do people with anxiety, low mood or poor sleep look at kratom?
The FDA says kratom is often used to self-treat conditions including pain, anxiety, depression, opioid use disorder and opioid withdrawal. The FDA also estimates that 1.7 million Americans aged 12 and older used kratom in 2021, based on SAMHSA’s National Survey on Drug Use and Health. The CDC report cites earlier studies that found about two-thirds of kratom users reported using it to manage depression or anxiety.
That explains why kratom turns up when you search for help with how you feel. It doesn’t answer whether it works, and the rest of this page covers that. If you’re not sure whether what you’re feeling is stress or something more, our piece on stress versus a mental health condition explains why self-labels have limits.
What is kratom?
Kratom (Mitragyna speciosa) is a tree in the coffee family, found in Thailand and neighboring countries, according to NCCIH. People in Southeast Asia have traditionally chewed its leaves or made them into a tea. Today it’s sold as whole or crushed leaves, powder, extract, encapsulated powder and extract resin “pies,” according to the DEA’s drug chemistry document on kratom.
Kratom contains at least 54 alkaloids. Mitragynine is the most abundant, at about 66% of total alkaloid content. 7-hydroxymitragynine (7-OH) is a minor alkaloid at less than 2%. Both mitragynine and 7-OH act on opioid receptors in the brain. People who use kratom have reported stimulant-like effects, such as more energy, alertness and a faster heart rate, and opioid- or sedative-like effects, such as relaxation, pain relief and confusion, according to NCCIH.
Leaf, extracts and concentrated 7-OH are different products
Leaf products, extracts and products with added or concentrated 7-OH are not interchangeable, and the research on each is different. The FDA says 7-OH is only a minor part of the leaf, but it has substantially greater mu-opioid receptor potency than mitragynine and morphine. The CDC notes that its poison-center data don’t show whether a case involved traditional leaf products or concentrated formulations such as 7-OH. When you read a study or a label, check which one it’s about before you apply the result to your own situation.
Is kratom legal?
The FDA says kratom is not lawfully marketed in the U.S. as a drug product, a dietary supplement or a food additive in conventional food. The DEA says kratom itself remains an unscheduled botanical and is not a controlled substance under the Controlled Substances Act. NCCIH notes that the DEA has listed kratom as a “drug of concern.”
The DEA has also placed three related compounds, MGPI, MGM-15 and MGM-16, into Schedule I, and the FDA reports that this was done on August 26, 2026. On October 14, 2026, the DEA published a Federal Register notice of intent about a proposed threshold approach for 7-OH and MGPI. Read that document as a notice of intent, the step the DEA itself describes it as.
State and local rules differ. The FDA says state health and law enforcement agencies are the best resource for applicable state laws.
What do the human studies actually show?
The FDA says there are few published reports from well-designed studies in which kratom was given to humans. The table below covers the human studies you’re most likely to see cited, with who took part, what they took, how long each ran, and what each study itself says limits its result.
| Study | People and size | Material and length | What it found | Limit the study states |
|---|---|---|---|---|
| Safety trial, Therapeutic Drug Monitoring, 2026 | 116 healthy volunteers: 49 given kratom, 67 given placebo. Nonsmoking, aged 18 to 55, and either never used kratom or hadn’t for at least 12 months. | Dried kratom leaf powder (MitraLeaf). Single doses, then 15 daily doses, over 47 days. | No serious adverse events or deaths. Most common after single doses: dizziness, nausea and feeling of relaxation. After daily doses: headache, feeling hot, raised ALT (a liver blood test) and nausea. | Healthy volunteers only. The authors’ conclusion applies to the dose ranges tested. |
| Abuse-potential study, Drug Testing and Analysis, 2026 | The same 116 volunteers and design. | The same leaf powder, single doses and 15 daily doses. | Modest, dose-related subjective effects. Effects lessened with repeated dosing. No one met the threshold for clinically meaningful opioid withdrawal on the COWS or SOWS scales. | The authors stress the importance of dose control and product standardization. |
| Pilot dose-finding study, J Clin Psychopharmacol, 2026 | 40 people who completed the study: recreational polydrug users with opioid experience, otherwise healthy. Eight per cohort, six active and two placebo. | Single doses of leaf material with trace 7-OH, escalating up to 12 g. One dose per person. | Somnolence, vomiting and nausea were the most common adverse events. Pupils constricted at 3 g and above. The 12 g dose raised ratings of drug liking, good effects and “high.” | The authors say the results may not represent other kratom-containing products. |
| Mitragynine study, Psychopharmacology, 2025 | 15 healthy volunteers (eight in part A, seven in part B). | Single doses of mitragynine alone, 5 to 40 mg, on separate days. Measured for 7 hours. | The lowest dose raised ratings of arousal and attention. The highest dose raised ratings of amnesia and produced mild psychopathological symptoms. Vital signs were not significantly affected. | A small, single-blind study of one compound, not a product. |
| Drug-interaction study, PubMed Central | 12 healthy adults. | A single 2 g dose of kratom tea. | A modest rise in midazolam exposure, a probe drug for one enzyme pathway. No change for dextromethorphan. The authors say co-consuming kratom with certain CYP3A-metabolized drugs may precipitate serious interactions. | A single low dose in 12 people. |
| Systematic review, Journal of Addictive Diseases, 2024 | Six published papers (one case series, five case reports), 10 cases, ages 28 to 55. | Case reports and one case series. Kratom use lasted from 2 weeks to 15 years. | Kratom use was associated with worsening psychotic and manic symptoms in people with psychiatric conditions. | Case reports describe individual patients. The authors say more research is required. |
| Meta-analysis, European Addiction Research, 2024 | 36 articles pooled. | Studies of kratom use and mental health indicators. Pooled, not a single trial. | A very small positive association with negative mental health indicators (r = 0.092). Internalizing disorders: r = -0.001, not significant. Substance use disorder association stronger in Malaysia (r = 0.347). The authors conclude the data support what they call the “kratom instrumentalization concept.” | Correlations across studies, not a test of whether kratom treats any condition. |
| CDC poison-center report, MMWR, 2026 | 14,449 kratom exposure reports to poison centers, 2015 to 2025, from 53 U.S. poison centers. 3,434 reports in 2025, against 258 in 2015. | Poison-center reports. The data do not separate leaf from concentrated products. | Suicide attempts were about one fourth of multiple-substance reports, compared with 6% of single-substance reports. Antidepressants were involved in 14% of multiple-substance reports. | Reports are voluntary and self-reported. They are not a rate of harm among all users. |
The 2026 trials were controlled, but they were run in healthy volunteers, not in people living with anxiety, depression or insomnia. That’s the first thing to hold onto when you read a headline about them.
The FDA also says it funded a single ascending dose study in humans. Its researchers have submitted a manuscript, and the results will be made public on acceptance. A 2026 study in the Journal of Analytical Toxicology looked at a concentrated extract (39.5% mitragynine) given as single and daily doses, and its authors reported that concentrated extracts may yield greater overall mitragynine exposure than dried leaf powder or tea at comparable doses. The paper discloses that all its authors are consultants to NP Pharma, LLC and were compensated for writing the manuscript.
What are the effects of kratom on the body?
NCCIH lists nausea, constipation, dizziness and drowsiness as mild side effects people have reported. It lists seizures, high blood pressure and liver problems as rare but serious effects. The DEA lists nausea, itching, sweating, dry mouth, constipation, increased urination and loss of appetite as acute side effects.
NCCIH also says fatal overdoses from kratom alone appear to be extremely rare, while use with other drugs has been linked to deaths and severe effects such as liver problems. It notes that harmful contaminants such as heavy metals and disease-causing bacteria have been found in some kratom products. In the pilot study, pupils constricted at doses of 3 g and above.
Can kratom cause dizziness?
Yes. NCCIH lists dizziness among the mild side effects people have reported, alongside nausea, constipation and drowsiness. In the 2026 trial of 116 healthy volunteers, dizziness was among the most common side effects after single doses.
What does kratom feel like the first time?
There’s no reliable answer, because the effect depends on the product, the amount and the person. NCCIH describes stimulant-like effects and opioid-like effects, both reported by people who use it. The DEA says that at low doses kratom produces stimulant effects such as alertness, physical energy and talkativeness. At high doses it produces sedation and euphoria. Effects occur within 5 to 10 minutes and last 2 to 5 hours.
In the trials, relaxation was among the common effects after single doses. Those volunteers had never used kratom or hadn’t for at least 12 months. Concentrated 7-OH products are a separate category, covered above.
How does kratom affect your personality?
The studies don’t say anything about personality as a whole. What they report is narrower. In the small mitragynine study, the lowest dose, 5 mg, raised ratings of arousal and attention, and the highest dose, 40 mg, raised ratings of amnesia and produced mild psychopathological symptoms. Psychosis and mania come from case reports. The 2024 systematic review found kratom use associated with worsening psychotic and manic symptoms in people with psychiatric conditions, across six papers and 10 cases. The authors write of “the possibility of worsening preexisting psychiatric conditions in the context of kratom use.”
The DEA says several cases of kratom psychosis have been observed. The 2024 meta-analysis found only a very small positive association between kratom use and negative mental health indicators. Those numbers describe patterns across studies, not what kratom does to any one person.
Does kratom mess with your serotonin?
Serotonin is one of the systems kratom touches. The FDA says mitragynine has additional actions on serotonin, dopamine, norepinephrine and kappa opioid receptors, alongside its main action on opioid receptors. The FDA also notes that what kratom does depends on how much is taken and under what conditions.
The practical concern is mixing. The CDC says kratom used with alcohol, opioids, benzodiazepines, stimulants and antidepressants might increase risk. In the 12-person drug-interaction study, a single 2 g dose of kratom tea modestly raised midazolam levels, which points to an effect on a drug-processing enzyme in the gut.
What happens if you take kratom every day?
The 2026 leaf-powder trial gave 15 daily doses to healthy volunteers. After daily doses, the most common side effects were headache, feeling hot, a raised ALT level and nausea. No one met the threshold for clinically meaningful opioid withdrawal, and subjective drug effects decreased with repeated dosing.
Those 15 days don’t tell you what long-term daily use does, and NCCIH says the long-term effects of kratom use are not well understood. The DEA lists what long-term use has produced in reports: anorexia, weight loss, insomnia, skin darkening, dry mouth, frequent urination, liver toxicity and constipation. NCCIH says there have been reports that long-term use of large doses may cause serious liver problems in some people.
Is 2 grams of kratom a day a lot?
The studies can’t give you a number to judge that by. The trials used single doses and 15 daily doses in healthy volunteers, and NCCIH says long-term effects are not well understood. The FDA reports that regular users who describe their own use say they take less than 6 grams of botanical kratom per use, based on several recent studies. That’s a self-report, not a safe limit, and it doesn’t tell you whether 2 grams is a lot for you.
What counts as a lot depends on the product, whether it’s leaf, extract or 7-OH, your health and what else you take. The CDC notes that its data don’t separate leaf from concentrated formulations, so the same gram count can mean very different things. Bring the question to your clinician, and see the section on clinician conversations below.
Does kratom change the way you look?
The DEA lists weight loss, reduced appetite, skin darkening and dry mouth among effects it says long-term use has produced. In the pilot study of a single dose, pupils got smaller at 3 g and above.
Can you become dependent on kratom?
The agencies say yes, it can happen. NCCIH says kratom itself may have the potential to be addictive, and regular users may have withdrawal symptoms if they stop. The DEA says kratom consumption can lead to addiction and reports withdrawal among chronic users. The FDA says cases of kratom-related substance use disorder have been observed. The CDC report notes that earlier studies found about one third of kratom users met criteria for another substance use disorder.
The 2026 trial showed a different picture: among healthy volunteers, no one met the threshold for clinically meaningful opioid withdrawal after 15 daily doses. That’s one short study in healthy people, and it sits next to the agencies’ warnings about regular users.
Is kratom a treatment for anxiety, depression or sleep problems?
NCCIH says kratom has not been shown to be safe and effective for this or any other medical use. The FDA says it has few well-designed human studies, and until its scientists can evaluate safety and effectiveness for any medical condition, it will continue to warn the public against using kratom for medical treatment.
The 2024 meta-analysis found a very small positive association (r = 0.092) between kratom use and negative mental health indicators. That is a correlation across studies, and it does not test whether kratom helps a condition. If you’re living with anxiety, low mood or poor sleep, the right test of any option is one run with a clinician who knows your history. If sleep is the main problem, our guide to sleep hygiene and mental health covers the sleep side.
Who should talk to a clinician before using kratom?
- If you’re pregnant or breastfeeding. The trials enrolled healthy adults, and the FDA says there are few well-designed human studies. Ask your clinician before using any kratom product.
- If you take prescription medicines. The CDC lists alcohol, opioids, benzodiazepines, stimulants and antidepressants as substances that might increase risk with kratom. NCCIH says more research is needed on drug interactions involving kratom.
- If you have liver disease. NCCIH reports that long-term use of large doses may cause serious liver problems, and that combinations with other drugs have been linked to liver problems. The FDA lists liver toxicity among its warnings.
- If you have a history of substance use. The CDC report notes that earlier studies found about one third of kratom users met criteria for another substance use disorder.
- If you have a psychiatric condition. The 2024 systematic review found kratom use associated with worsening psychotic and manic symptoms in people with psychiatric conditions.
How do I bring kratom up with my clinician?
Bring the product name and label, and say whether it’s leaf, extract or a product with 7-OH. Tell them how often you take it, and list everything else you use, including alcohol and other substances. Then ask whether it could interact with your current medicines, and what they’d suggest for your sleep, mood or anxiety. Our guide to preparing for a mental health conversation covers goals, questions and follow-up.
Where can I get help right now?
- Emergency: call 911.
- Suicidal thoughts or behavior: reach the Suicide & Crisis Lifeline at 988.
- Veterans: the Veterans Crisis Line is reached by dialing 988, then pressing 1.
- Treatment: free or low-cost treatment is available through SAMHSA, and health centers and your state’s mental health or substance abuse agency can help. The USA.gov mental health help page lists these options.
- Report a bad reaction: the FDA encourages consumers to report adverse reactions through MedWatch, by phone at 1-800-332-1088 or online.
- General information: the NCCIH Clearinghouse can be reached at 1-888-644-6226. It provides information, not medical advice or referrals.
What other options should I compare kratom with?
Compare kratom with other options on the same terms: what the studies measured, in whom, and for how long. Our guide to mental health supplements looks at what research shows for anxiety and depression. For a separate look at the research on kratom’s benefits and safety, see kratom benefits evidence (our research library).
By the Global MH Summit Research Team